+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Myeloma"

Molecular Hematology. Edition No. 5 - Product Thumbnail Image

Molecular Hematology. Edition No. 5

  • Book
  • April 2024
  • 448 Pages
Haematology. Edition No. 11. Lecture Notes - Product Thumbnail Image

Haematology. Edition No. 11. Lecture Notes

  • Book
  • November 2022
  • 208 Pages
Skin Lymphoma. The Illustrated Guide. Edition No. 5 - Product Thumbnail Image

Skin Lymphoma. The Illustrated Guide. Edition No. 5

  • Book
  • October 2020
  • 600 Pages
Molecular Hematology. Edition No. 4 - Product Thumbnail Image

Molecular Hematology. Edition No. 4

  • Book
  • November 2019
  • 432 Pages
Postgraduate Haematology. Edition No. 7 - Product Thumbnail Image

Postgraduate Haematology. Edition No. 7

  • Book
  • January 2016
  • 952 Pages
Molecular Hematology. Edition No. 4 - Product Thumbnail Image

Molecular Hematology. Edition No. 4

  • Book
  • November 2019
  • 432 Pages
Loading Indicator

Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of hematological malignancy, which is a cancer of the blood or bone marrow. Myeloma is the second most common type of hematological malignancy, after lymphoma. Symptoms of myeloma include bone pain, anemia, frequent infections, and kidney problems. Treatment options include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. The myeloma market is a subset of the hematology market, which is a large and growing market. The market is driven by the increasing prevalence of hematological malignancies, as well as advances in treatment options. The market is expected to continue to grow in the coming years, as new treatments are developed and more patients are diagnosed. Some companies in the myeloma market include Bristol-Myers Squibb, Celgene, Novartis, and Takeda. Show Less Read more